ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate

ADMA Biologics Inc (NASDAQ:ADMA) is a biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies and infectious diseases. The stock has shown strong technical and fundamental characteristics that align with Mark Minervini’s Trend Template, making it a potential candidate for further analysis.

Why ADMA Fits the Minervini Trend Template

Mark Minervini’s Trend Template identifies stocks in strong uptrends with accelerating fundamentals. ADMA meets several key criteria:

Technical Strength

• Price Above Key Moving Averages: ADMA trades at $23.80, well above its 50-day ($19.07), 150-day ($18.50), and 200-day ($17.83) moving averages.
• Upward-Trending Averages: The 50-day, 150-day, and 200-day moving averages are all rising, confirming long-term bullish momentum.
• Relative Strength: With a ChartMill Relative Strength (CRS) score of 99.15, ADMA outperforms nearly all stocks in its sector.
• Near 52-Week High: The stock is trading within 7.3% of its 52-week high ($25.67), indicating strong momentum.

Fundamental Growth

• Earnings Growth: ADMA’s EPS grew 484.6% year-over-year (TTM), with recent quarterly growth of 275%.
• Revenue Growth: Sales increased 65.2% over the past year, with consistent quarterly growth above 59%.
• Profit Margins: The latest quarter saw a 95.2% profit margin, a significant improvement from prior quarters.

Technical Analysis Summary

According to ChartMill’s technical report, ADMA scores a perfect 10 on technical health, with both short-term and long-term trends positive. Key takeaways:

• Strong Uptrend: The stock has consistently outperformed the broader market.
• Support Levels: Key support zones exist at $19.07, $17.65, and $15.70, providing downside protection.
• High Liquidity: Average daily volume of 3.55M shares ensures smooth trading.

While the stock does not currently offer a high-quality setup due to recent volatility, its strong technical and fundamental profile makes it one to watch for consolidation opportunities.

Conclusion

ADMA Biologics (NASDAQ:ADMA) demonstrates the hallmarks of a Minervini-style growth stock—strong price action, rising fundamentals, and sector leadership. Investors should monitor for potential entry points during pullbacks or consolidations.

For more high-growth momentum stocks, check out the [full screener results](https://www.chartmill.com/stock/stock-screener?sid=718&f=sm50v_a_sm150v,sm50v_a_sm200v,sl_crs_70_X,sm200v_r,sm150v_a_sm200v,v1_50b100,cu_a_sm50v,cu_a_sm150v,cu_a_sm200v,sl_ratingHgm_6_X,exch_us&v=3&s=ta&sd=DESC&cpl=2&bc=true&nw=1&pam=1&pm=1&set=1&uc=7054723&dc=14111810&o1=3&op1=200,16711680&o2=3&op2=50,255&o3=1&o4=89&op4=40,1,10536676&cf=(h%3E%3D(wh520.75)),(cu%3E%3D(wl521.3)).